The debate over the accessibility and long-term sustainability of weight-loss drugs like Wegovy and Mounjaro is a complex and multifaceted issue. These medications, while offering significant health benefits, come with a high price tag, creating a stark divide between those who can afford them and those who cannot. This divide is not just financial; it also impacts the psychological and physical well-being of individuals, as evidenced by the stories of Kirsty, Alison, and Rosie.
Kirsty, a 33-year-old single mother from the Manawatū region, highlights the financial burden of these drugs. She had to make difficult choices, such as canceling her personal trainer and putting her studies on hold, to afford the $400 monthly cost of Wegovy. Despite her efforts, the recent rise in petrol and food prices made it impossible for her to continue the injections. Kirsty's experience underscores the harsh reality that these medications are not accessible to everyone, and the consequences of discontinuing them can be severe.
Alison, in her 50s from Christchurch, shares a similar story. She lost 20 kilos in seven months with Wegovy but is now slowly reducing her dose due to financial constraints and side effects. The return of food noise and the resurgence of inflammation in her face are stark reminders of the challenges of maintaining weight loss without the medication. Alison's experience highlights the psychological impact of these drugs and the difficulty of breaking the cycle of food obsession.
Rosie, a 44-year-old from Nelson with PMOS, has a different perspective. She has lost a significant amount of weight with Wegovy and Saxenda and predicts she will take these medications for the rest of her life. Rosie's approach is to view the medications as necessary treatments for her genetic condition, similar to taking medication for high blood pressure. This perspective highlights the importance of individual health needs and the potential for long-term reliance on these drugs.
The underlying issue is the set point weight theory, which suggests that each person has a predetermined weight or weight range that their body will instinctively try to maintain. When individuals stop taking weight-loss medications, their bodies often work to regain the lost weight. This is supported by research showing that weight gain is four times faster for those who stop medications compared to those who stop conventional diet and exercise strategies. However, some individuals, like Rosie, are able to maintain their weight loss and may even continue to benefit from the medications long-term.
The debate over the accessibility and long-term sustainability of these drugs is a complex one. While the medications offer significant health benefits, the financial burden and potential for rapid weight regain are significant concerns. The stories of Kirsty, Alison, and Rosie highlight the human impact of this issue, and the need for a nuanced approach that considers both the benefits and challenges of these medications.
